Johnson & Johnson (JNJ)vsOncology Institute Inc (TOI)
JNJ
Johnson & Johnson
$227.19
-1.16%
HEALTHCARE · Cap: $547.28B
TOI
Oncology Institute Inc
$4.05
+4.92%
HEALTHCARE · Cap: $366.69M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 19068% more annual revenue ($96.36B vs $502.73M). JNJ leads profitability with a 21.8% profit margin vs -12.1%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-41.6%
Fair Value
$160.43
Current Price
$227.19
$66.76 premium
Margin of Safety
+80.1%
Fair Value
$13.17
Current Price
$4.05
$9.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Revenue surging 41.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -652.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.6% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TOI is a hypergrowth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.33 — expect wider price swings.
TOI is growing revenue faster at 41.6% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 45/100), backed by strong 21.8% margins. TOI offers better value entry with a 80.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a pioneering healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment modalities. The company prioritizes enhanced patient outcomes by leveraging state-of-the-art technologies and customized treatment plans, while also participating in clinical trials and collaborations with leading research institutions. As the need for advanced cancer therapies continues to grow, TOI is strategically positioned to leverage its robust pipeline and deep-seated oncology expertise, reinforcing its status as a key player in the evolving healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?